BLAINJECTIONINJECTABLE
Approved
Apr 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
CIMZIA (certolizumab pegol) by UCB Pharma is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2008.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIMZIA (certolizumab pegol) is a PEGylated TNF-alpha inhibitor monoclonal antibody fragment approved in 2008 for inflammatory conditions including rheumatoid arthritis and Crohn's disease. It blocks tumor necrosis factor receptor signaling to reduce inflammation. The drug is administered via subcutaneous injection and represents a pegylated humanized antibody fragment designed for extended half-life.
$0.275BPart D
LOE ApproachingDeclining
12-15% of TNF inhibitor class
Mature product in managed decline with smaller-scale commercial infrastructure; teams are being consolidated or repositioned toward emerging programs.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
Started Jun 2021
0Crohn's Disease
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
Started Feb 2021
33 enrolled
Rheumatoid Arthritis
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
Started Jun 2020
22 enrolled
Rheumatoid ArthritisPsoriatic ArthritisCrohn's Disease+2 more
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
Started Jan 2020
49 enrolled
Moderate Chronic Plaque PsoriasisSevere Chronic Plaque PsoriasisMixed Guttate/Plaque Psoriasis
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
Started Aug 2019
412 enrolled
Plaque Psoriasis
Worked on CIMZIA at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.